With the advent and increasing uptake of screening programs, the incidence of early stage, hormone receptor positive (HR + )/luminal-like [estrogen receptor positive (ER + ) and/or progesterone receptor positive (PR + )] breast cancer has continued to rise [2, 3]. This evidence concerns the gene ESR1 and breast cancer.